Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $188.00 at Piper Sandler

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective hoisted by equities researchers at Piper Sandler from $171.00 to $188.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s target price suggests a potential upside of 51.49% from the company’s current price.

JAZZ has been the topic of a number of other reports. Royal Bank of Canada restated an “outperform” rating and set a $195.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. JPMorgan Chase & Co. cut their target price on shares of Jazz Pharmaceuticals from $180.00 to $170.00 and set an “overweight” rating on the stock in a research note on Thursday, February 29th. Stifel Nicolaus upped their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a report on Friday, March 15th. Truist Financial reaffirmed a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, December 4th. Finally, Needham & Company LLC lowered their price target on Jazz Pharmaceuticals from $225.00 to $220.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $193.42.

Jazz Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:JAZZ opened at $124.10 on Wednesday. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The firm has a market capitalization of $7.82 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 1.72 and a beta of 0.59. The firm’s 50-day moving average is $122.47 and its two-hundred day moving average is $125.19. Jazz Pharmaceuticals has a 1 year low of $111.25 and a 1 year high of $147.98.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Analysts predict that Jazz Pharmaceuticals will post 16.3 EPS for the current year.

Insider Activity

In other news, CFO Philip L. Johnson acquired 12,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was acquired at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Philip L. Johnson acquired 12,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was acquired at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Virtu Financial LLC raised its stake in shares of Jazz Pharmaceuticals by 104.6% during the fourth quarter. Virtu Financial LLC now owns 8,877 shares of the specialty pharmaceutical company’s stock worth $1,092,000 after purchasing an additional 4,538 shares during the last quarter. V Square Quantitative Management LLC raised its position in Jazz Pharmaceuticals by 63.9% in the fourth quarter. V Square Quantitative Management LLC now owns 680 shares of the specialty pharmaceutical company’s stock worth $84,000 after acquiring an additional 265 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Jazz Pharmaceuticals by 63.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 48,344 shares of the specialty pharmaceutical company’s stock worth $5,948,000 after acquiring an additional 18,796 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $7,077,000. Finally, GSA Capital Partners LLP purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $208,000. Hedge funds and other institutional investors own 88.15% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.